#NOVAMIND STOCK REDDIT UPDATE#
#NOVAMIND STOCK REDDIT TRIAL#

One executive has even gone as far as claiming that psychedelic pharma will usher in a new вЂњspiritualized humanityвЂќ by 2070. BronnerвЂ™s ) uncritical news segments on networks like Fox and CNN and endless celebrity endorsements. These have included collaborations between psychedelic research groups and various вЂњ crunchy вЂќ businesses (such as Goop and Dr. However, the entrance of these drugs onto the mainstream stage has already spawned a number of questionable media and marketing stunts.

#NOVAMIND STOCK REDDIT UPDATE#

The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.T he budding psychedelics industry is full of individuals and organizations ideologically and financially invested in presenting the field as rooted in rigorous, buttoned-up science. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information. Important factors that could cause actual results to differ materially from the Company's expectations including the risks detailed from time to time in the Company's public disclosure.

There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. This news release contains forward-looking statements. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of integrative mental health clinics and operates a full-service contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine.

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. To learn more about the Psilocybin Trial, please visit this link. This work is truly ground-breaking, and we are incredibly honoured to contribute and advance the fields of psychedelic medicine and psychiatry.'

#NOVAMIND STOCK REDDIT TRIAL#

Reid Robison, Chief Medical Officer and Principal Investigator of the Psilocybin Trial at Novamind's research site, added, 'While previous small-scale studies have provided encouraging evidence for the use of psilocybin for depression, phase II trials will help us better evaluate the safety and effectiveness of the medication. With specialized infrastructure and expertise in psychedelic medicine, we're uniquely suited to bring the highest research standards to the evaluation of psilocybin as a treatment for depression.'Дr. Thielking continued, 'Novamind's contract research division is devoted to responsibly managing all stages of clinical trials for neuropsychiatry. Drug Enforcement Agency to store and administer psilocybin for research, qualifying the Company to host future psilocybin clinical trials at its sites.Дr. Last year, Novamind was awarded two Schedule 1 Licenses from the U.S. Recent regulatory shifts supporting psilocybin research also acknowledge the unmet need and the potential for improved, novel therapeutic options. With an estimated 280 million people worldwide suffering from depression, 1 psilocybin has been steadily gaining recognition as a potential therapy to help address a growing global mental health crisis. Today marks another exciting milestone for our team as we continue to support drug developers, not-for-profits and academic partners to accelerate psychedelic research and improve patient outcomes.' Paul Thielking, Chief Scientific Officer at Novamind, commented, 'The Psilocybin Trial is a key step in moving psilocybin through the clinical development process and closer to regulatory approval. Today the Company completed first patient randomization at its Draper, Utah research site.Дr. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ('Novamind' or the 'Company'), a leading mental health company specialized in psychedelic medicine, is pleased to conduct a phase II clinical trial investigating psilocybin for major depressive disorder (MDD) sponsored by the Usona Institute (the 'Psilocybin Trial'). TORONTO, ON / ACCESSWIRE / Ma/ Novamind Inc. First patient randomization completed at Draper, Utah research site

Novamind stock reddit